165 related articles for article (PubMed ID: 30844857)
1. Targeting proprotein convertase subtilisin/kexin type 9 in mice and monkeys.
Wang Y; Ma M; Wang JA; Daugherty A; Lu HS
Curr Opin Lipidol; 2019 Apr; 30(2):154-155. PubMed ID: 30844857
[No Abstract] [Full Text] [Related]
2. Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in C57BL/6 Mice-Brief Report.
Lu H; Howatt DA; Balakrishnan A; Graham MJ; Mullick AE; Daugherty A
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1753-7. PubMed ID: 27470509
[TBL] [Abstract][Full Text] [Related]
3. Induction of atherosclerosis in mice and hamsters without germline genetic engineering.
Bjørklund MM; Hollensen AK; Hagensen MK; Dagnaes-Hansen F; Christoffersen C; Mikkelsen JG; Bentzon JF
Circ Res; 2014 May; 114(11):1684-9. PubMed ID: 24677271
[TBL] [Abstract][Full Text] [Related]
4. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
[TBL] [Abstract][Full Text] [Related]
5. STK25 Regulates Cardiovascular Disease Progression in a Mouse Model of Hypercholesterolemia.
Cansby E; Magnusson E; Nuñez-Durán E; Amrutkar M; Pedrelli M; Parini P; Hoffmann J; Ståhlman M; Howell BW; Marschall HU; Borén J; Mahlapuu M
Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1723-1737. PubMed ID: 29930001
[TBL] [Abstract][Full Text] [Related]
6. Induction of sustained hypercholesterolemia by single adeno-associated virus-mediated gene transfer of mutant hPCSK9.
Roche-Molina M; Sanz-Rosa D; Cruz FM; García-Prieto J; López S; Abia R; Muriana FJ; Fuster V; Ibáñez B; Bernal JA
Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):50-9. PubMed ID: 25341796
[TBL] [Abstract][Full Text] [Related]
7. Significance of Monoclonal PCSK9-Antibodies - New Approaches to the Therapy of Hypercholesterolemia.
Neumann CL; Schettler E; Schettler VJ
Blood Purif; 2016; 41(4):270-6. PubMed ID: 26789774
[TBL] [Abstract][Full Text] [Related]
8. Atherosclerosis Induced by Adeno-Associated Virus Encoding Gain-of-Function PCSK9.
Bjørklund MM; Bernal JA; Bentzon JF
Methods Mol Biol; 2022; 2419():461-473. PubMed ID: 35237981
[TBL] [Abstract][Full Text] [Related]
9. The LEPIS-HuR-TMOD4 axis regulates hepatic cholesterol homeostasis and accelerates atherosclerosis.
LYu P; Pan H; Hu K; Xue Y; Li Q; Lin R; Zheng S; Guo Z; Guo K
Atherosclerosis; 2024 Jun; 393():117554. PubMed ID: 38663275
[TBL] [Abstract][Full Text] [Related]
10. Somatic Editing of Ldlr With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research.
Jarrett KE; Lee C; De Giorgi M; Hurley A; Gillard BK; Doerfler AM; Li A; Pownall HJ; Bao G; Lagor WR
Arterioscler Thromb Vasc Biol; 2018 Sep; 38(9):1997-2006. PubMed ID: 30026278
[TBL] [Abstract][Full Text] [Related]
11. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
Seidah NG; Prat A; Pirillo A; Catapano AL; Norata GD
Cardiovasc Res; 2019 Mar; 115(3):510-518. PubMed ID: 30629143
[TBL] [Abstract][Full Text] [Related]
12. Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol.
Seidah NG
Nat Struct Mol Biol; 2017 Oct; 24(10):785-786. PubMed ID: 28981076
[No Abstract] [Full Text] [Related]
13. Absence of Nicotinamide Nucleotide Transhydrogenase in C57BL/6J Mice Exacerbates Experimental Atherosclerosis.
Vozenilek AE; Vetkoetter M; Green JM; Shen X; Traylor JG; Klein RL; Orr AW; Woolard MD; Krzywanski DM
J Vasc Res; 2018; 55(2):98-110. PubMed ID: 29455203
[TBL] [Abstract][Full Text] [Related]
14. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
15. Meganuclease targeting of PCSK9 in macaque liver leads to stable reduction in serum cholesterol.
Wang L; Smith J; Breton C; Clark P; Zhang J; Ying L; Che Y; Lape J; Bell P; Calcedo R; Buza EL; Saveliev A; Bartsevich VV; He Z; White J; Li M; Jantz D; Wilson JM
Nat Biotechnol; 2018 Sep; 36(8):717-725. PubMed ID: 29985478
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of proprotein convertase subtilisin/kexin type 9 in the treatment of hypercholesterolemia.
Ascaso JF
Endocrinol Nutr; 2016; 63(6):255-7. PubMed ID: 27050861
[No Abstract] [Full Text] [Related]
17. Vaccine Against PCSK9 Improved Renal Fibrosis by Regulating Fatty Acid β-Oxidation.
Wu D; Zhou Y; Pan Y; Li C; Wang Y; Chen F; Chen X; Yang S; Zhou Z; Liao Y; Qiu Z
J Am Heart Assoc; 2020 Jan; 9(1):e014358. PubMed ID: 31870234
[TBL] [Abstract][Full Text] [Related]
18. Effects of Inhibition or Deletion of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) on Intracerebral Hemorrhage Volumes in Mice.
Schlunk F; Fischer P; Princen HMG; Rex A; Prinz V; Foddis M; Lütjohann D; Laufs U; Endres M
Stroke; 2020 Nov; 51(11):e297-e298. PubMed ID: 33070710
[No Abstract] [Full Text] [Related]
19. Potential role of lycopene in targeting proprotein convertase subtilisin/kexin type-9 to combat hypercholesterolemia.
Sultan Alvi S; Ansari IA; Khan I; Iqbal J; Khan MS
Free Radic Biol Med; 2017 Jul; 108():394-403. PubMed ID: 28412198
[TBL] [Abstract][Full Text] [Related]
20. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
